Last checked at 8 Feb 2022 07:00
IXICO plc
("IXICO" or the "Company")
Contract award worth circa £1.0m for Phase 1b/2 trial in neurodegenerative diseases
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience is pleased to announce that it has been selected to provide PET and MRI imaging services to a leading European biopharmaceutical company specialising in neurodegenerative conditions. The trial is a Phase 1b/2 clinical trial and relates to the use of a novel compound to target amyloid in neurodegenerative diseases.
The sponsor is a new client for IXICO, and this trial will run over approximately five years. This study will include participants with Alzheimer's disease ('AD') as well as participants with Down Syndrome. AD continues to be the number one indication in clinical research with a continued focus on the amyloid target. This study confirms IXICO's leading role supporting sponsors dedicated to finding treatments for this disease.
IXICO is providing end to end support to the sponsor for this trial: from consultation in planning and design of the imaging protocols to the set up and management of imaging centres, collection and control of imaging data (including Amyloid and Tau PET), radiology and subsequent analysis and reporting of data.
Having built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders, IXICO is able to provide advanced neuroimaging solutions and services from Phase I through to commercialisation. In this trial, IXICO will deploy a range of advanced MRI modalities, including volumetric, diffusion (DTI), perfusion (ASL) and functional (BOLD) MRI. IXICO will provide radiology and quantitative analysis services to support patient selection, safety, and efficacy analysis.
Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be awarded this contract. Our success in being awarded this study with another new client follows on from our success in securing contracts with nine new clients during the last financial year and is a further contract that utilises both our MRI and PET service portfolios. Our mission is to support our clients in their tireless efforts to bring potential treatments to patients suffering from neurological disorders, and this contract reflects the confidence that increasing numbers of companies are placing in IXICO as their trusted neuroimaging partner for their important CNS studies."
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
| ||||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Tamar Cranford-Smith (Sales) |
| |||
| ||||
Walbrook PR Ltd | IXICO@walbrookpr.com | |||
Paul McManus / Lianne Applegarth /Alice Woodings | +44 (0)20 7933 8780
| |||
About IXICO | Advanced Analytics | Intelligent Insights.
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews